Conflict of interest: Nothing to declare.
Clinical Practice Guideline
Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years†
Article first published online: 25 OCT 2012
Copyright © 2012 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 60, Issue 2, pages 175–184, February 2013
How to Cite
Haupt, R., Minkov, M., Astigarraga, I., Schäfer, E., Nanduri, V., Jubran, R., Egeler, R. M., Janka, G., Micic, D., Rodriguez-Galindo, C., Van Gool, S., Visser, J., Weitzman, S., Donadieu, J. and for the Euro Histio Network (2013), Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr. Blood Cancer, 60: 175–184. doi: 10.1002/pbc.24367
- Issue published online: 14 DEC 2012
- Article first published online: 25 OCT 2012
- Manuscript Accepted: 18 SEP 2012
- Manuscript Received: 13 MAY 2012
- clinical work-up;
- Langerhans cell histiocytosis;
These guidelines for the management of patients up to 18 years with Langerhans cell histiocytosis (LCH) have been set up by a group of experts involved in the Euro Histio Net project who participated in national or international studies and in peer reviewed publications. Existing guidelines were reviewed and changed where new evidence was available in the literature up to 2012. Data and publications have been ranked according to evidence based medicine and when there was a lack of published data, consensus between experts was sought. Guidelines for diagnosis, initial clinical work-up, and treatment and long-term follow-up of LCH patients are presented. Pediatr Blood Cancer 2013;60:175–184. © 2012 Wiley Periodicals, Inc.